Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M606148200 on December 17, 2006

J. Biol. Chem., Vol. 282, Issue 7, 4932-4942, February 16, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/7/4932    most recent
M606148200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orlandi, A.
Right arrow Articles by Spagnoli, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orlandi, A.
Right arrow Articles by Spagnoli, L. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Propionyl-L-carnitine Reduces Proliferation and Potentiates Bax-related Apoptosis of Aortic Intimal Smooth Muscle Cells by Modulating Nuclear Factor-{kappa}B Activity*

Augusto Orlandi{ddagger}1, Arianna Francesconi{ddagger}, Marcella Marcellini§, Antonio Di Lascio{ddagger}, and Luigi Giusto Spagnoli{ddagger}

From the {ddagger}Institute of Anatomic Pathology, Tor Vergata University, Rome 00133, Italy and §Sigma-Tau Research Laboratories, Pomezia (Rome) 00040, Italy

Propionyl-L-carnitine (PLC) has been introduced among the therapeutic approaches of peripheral arterial disease, and more recently, an increase of intimal cell apoptosis has been demonstrated to contribute to its effectiveness in rabbit carotid postinjury myointimal hyperplasia prevention. How PLC mediates these effects on vascular smooth muscle cells (SMCs) remains poorly understood. We investigated the role of NF-{kappa}B in PLC-induced arterial remodeling. In vivo, daily PLC treatment 15 days after injury resulted in a reduction of relative rat aortic intimal volume, an increase of apoptosis, Bax up-regulation without changing the Bcl-2 level, and a reduction of NF-{kappa}B, vascular cell adhesion molecule-1, monocyte chemotactic protein-1, and survivin in myointimal thickening compared with controls. In the presence of 10% serum, a reduced G1 -> S phase progression preceded PLC-induced intimal cell apoptosis; in 0.1% serum cultures, in a dose-dependent manner, PLC rapidly induced intimal cell apoptosis and reduced p65, p50, IAP-1, and IAP-2 expression. Inhibiting NF-{kappa}B activation through SN50 increased apoptotic rate and Bax expression in intimal but not in medial SMCs, and successive PLC treatment failed to induce a further increase in apoptotic rate. Bax antisense oligodeoxynucleotide reduced PLC-induced intimal cell apoptosis and cytochrome c release. The PLC-induced attenuation of NF-{kappa}B activity in intimal cells was also due to the increase of I{kappa}B-{alpha} bioavailability, as the result of a parallel induction of I{kappa}B-{alpha} synthesis and reduction of phosphorylation and degradation. Collectively, these findings document that NF-{kappa}B activity inhibition contributes to PLC-induced proliferative arrest and Bax-related apoptosis of intimal SMCs.


Received for publication, June 27, 2006 , and in revised form, November 22, 2006.

The nucleotide sequence(s) reported in this paper has been submitted to the Gen-BankTM/EBI Data Bank with accession number(s) NM_023987 [GenBank] , AF_190020, X63722 [GenBank] , NM_031530 [GenBank] , X02231 [GenBank] , XM_343065 [GenBank] , NM_199267 [GenBank] , and XM_342346 [GenBank] .

* This study was supported in part by a grant from Spedali Civili of Brescia (Protocol 20906055) and Sigma Tau (Pomezia) for animal maintenance. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: Anatomic Pathology Institute, Dept. Biopathology and Image Diagnostics, Tor Vergata University, Via Montpellier 1, 00133 Rome, Italy. Tel.: 39-06-20903960; Fax: 39-06-20902209; E-mail: orlandi{at}uniroma2.it.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
C. Pisano, M. De Cesare, G. L. Beretta, V. Zuco, G. Pratesi, S. Penco, L. Vesci, R. Fodera, F. F. Ferrara, M. B. Guglielmi, et al.
Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968
Mol. Cancer Ther., July 1, 2008; 7(7): 2051 - 2059.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement